Skip to main content
Arjan Diepstra
dr.

As a hematopathologist, I work on diagnostics of all types of hematological malignancies using a comprehensive panel of different techniques. Moreover, my main research interest involves Hodgkin lymphoma, with a strong focus on interactions between tumor cells and the microenvironment. In addition, I also have a long standing interest in genetic susceptibility. My areas of expertise are: immunology, tumor cell biology, genetic association studies and molecular diagnostics in pathology. I actively participate in international (EORTC) and national (HOVON) clinical trials.

Expression of HLA Class I and HLA Class II by Tumor Cells in Chinese Classical Hodgkin Lymphoma Patients
Published in: PLoS ONE
Background: In Caucasian populations, the tumor cells of Epstein Barr virus (EBV)-positive classical Hodgkin Lymphomas (cHL) patients more frequently express HLA class I and HLA class II molecules compared to EBV-negative cHL patients. HLA expression (in relation to EBV) in Asian cHL patients has not been previously investigated. Methodology/Principal Findings: We randomly selected 145 cHL patients with formalin-fixed, paraffin embedded tissue blocks available from 5 hospitals from the Northern part of China. Hematoxylin & Eosin-stained slides were used to reclassify the histological subtypes according to the WHO classification....
Xin Huang, Anke van den Berg, Zifen Gao, Lydia Visser, Ilja Nolte, Hans Vos, Bouke Hepkema, Wierd Kooistra, Sibrand Poppema, Arjan Diepstra
Endoscopic detection of an early manifestation of EBV-related post-transplant lymphoproliferative disorder in a transplanted colon
Published in: Endoscopy
M. W. van Ginkel, A. Diepstra, G. Dijkstra, V. B. Nieuwenhuijs, Z. J. de Langen, E. H. H. M. Rings
Latent Epstein-Barr Virus Infection of Tumor Cells in Classical Hodgkin’s Lymphoma Predicts Adverse Outcome in Older Adult Patients
Published in: Journal of Clinical Oncology
Purpose In classical Hodgkin’s lymphoma (cHL), the impact of tumor cell Epstein-Barr virus (EBV) status on clinical outcome is controversial. Patients and Methods We assessed failure-free survival (FFS) and relative survival (RS) in 412 patients with cHL and age-defined subgroups in a population-based study in the northern Netherlands. Tumor cell EBV status was positive in 34%, and the median follow-up time was 7.1 years. Patients’ median age at diagnosis was 35 years (range, 7 to 91 years), and 63% had Ann Arbor stage I or II, 24% had...
Arjan Diepstra, Gustaaf W. van Imhoff, Michael Schaapveld, Henrike Karim-Kos, Anke van den Berg, Edo Vellenga, Sibrand Poppema
miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes
Published in: Laboratory Investigation
MicroRNAs ( miRNAs) are an important class of small RNAs that regulate gene expression at the post-transcriptional level. It has become evident that miRNAs are involved in hematopoiesis, and that deregulation of miRNAs may give rise to hematopoietic malignancies. The aim of our study was to establish miRNA profiles of naive, germinal center ( GC) and memory B cells, and validate their expression patterns in normal lymphoid tissues. Quantitative (q) RT-PCR profiling revealed that several miRNAs were elevated in GC B cells, including miR-17-5p, miR-106a and miR-181b. One...
Lu Ping Tan, Miao Wang, Jan-Lukas Robertus, Rikst Nynke Schakel, Johan H. Gibcus, Arjan Diepstra, Geert Harms, Suat-Cheng Peh, Rogier M. Reijmers, Steven T. Pals, Bart-Jan Kroesen, Philip M. Kluin, Sibrand Poppema, Anke van den Berg
Beneath the Surface
Published in: American Journal of Medicine
H. A. Martens, J. J. Koornstra, A. Diepstra, H. G. Sprenger, C. G. M. Kallenberg